H.C. Wainwright analyst Yi Chen has reiterated their bullish stance on LFMD stock, giving a Buy rating today.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Yi Chen has given his Buy rating due to a combination of factors that highlight LifeMD’s strategic positioning and financial performance. Despite a slight miss in third-quarter revenue projections, LifeMD demonstrated a year-over-year growth in telehealth revenue and an increase in its active subscriber base. The company’s decision to divest its majority ownership in WorkSimpli has positioned it as a focused telehealth and pharmacy platform, which is expected to drive future growth.
Furthermore, LifeMD’s financial health is underscored by its cash position and the complete payoff of its long-term debt, which enhances its financial flexibility. The company’s adjusted EBITDA performance and updated revenue guidance reflect its resilience amid competitive pressures in the weight management market. Based on these factors and a valuation analysis using an EV/Revenue multiple, Yi Chen has set a 12-month price target of $9, reiterating the Buy rating for LifeMD.
Chen covers the Healthcare sector, focusing on stocks such as RegenXBio, Formycon AG, and VolitionRX. According to TipRanks, Chen has an average return of -6.9% and a 39.44% success rate on recommended stocks.